A study published recently in The Prostate suggests patients with hyperlipidaemia may have an increased risk for developing clinical benign prostate hyperplasia (BPH).
In a longitudinal cohort study, researchers analysed data from the Taiwan National Health Insurance Database to determine the incidence of BPH among individuals with newly diagnosed hyperlipidaemia (n= 8965) and their age- and index-date-matched non-hyperlipidaemia counterparts (n=26,895).
Compared with non-hyperlipidaemia individuals, those with hyperlipidaemia were found to have a substantially higher incidence of BPH (12.3% vs 24.6%; P<.001) as well as treated BPH (5.7% vs 13%; P<.001). The hyperlipidaemia cohort had a substantially higher risk for BPH compared with the non-hyperlipidaemia cohort (HR, 2.21; P<.001). This increased risk for BPH remained significant after adjusting for various confounders.
The definitive mechanisms underlying the association between hyperlipidaemia and BPH still remain unclear. The authors speculate that chronic inflammation caused by lipids could be a possible mechanism. This is further supported by previous studies which have shown anti-inflammatory agents such as metformin and NSAIDs to reduce BPH risk.
"Effective and early control of hyperlipidaemia may be beneficial in preventing BPH and, as such, reducing the incidence of treated BPH," the authors believe.